ASSESSMENT OF POTENTIAL COCAINE TREATMENT MEDICATIONS

这代表着NIDA合同N01DA29305的竞争性续签， 题为《#年潜在可卡因治疗药物的评估》 这份研究和开发合同的目标是 测定化合物对啮齿动物运动活动的影响 和毒品歧视程序作为评估其 作为可卡因治疗药物的潜在疗效。这些测试已经 被NIDA药物开发部(MDD)选中 可卡因治疗发现计划(CTDP)，因为他们 被认为代表了可能预测临床的模型系统 可卡因依赖药物治疗的疗效。数据 NIDA/MDD/CTDP将利用该合同生成的数据 用于额外的临床前评估的化合物的选择和 可卡因药物疗法的后续发展 依赖。简而言之，承包商将在 小鼠活动试验和大鼠药物辨别试验。我们 关于运动活动程序，运动的影响 复方，单独或与可卡因联合使用， 将评估小鼠的运动活动。视结果而定 从运动能力测试中得到的化合物，要么是 评估对抗歧视(主观)的能力 可卡因的效果或用来替代歧视性的(主观) 可卡因的影响。这份合同的预期最终结果是 详细说明研究结果的书面报告。

This represents a competitive renewal of NIDA contract N01DA29305, entitled "Assessment of Potential Cocaine Treatment Medications in Rodents". The objectives of this research and development contract is to determine the effects of compounds in the rodent locomotor activity and drug discrimination procedures as a means of evaluating their potential efficacy as cocaine treatment medications. These tests have been selected by NIDA Medication Development Division's (MDD) Cocaine Treatment Discovery Program (CTDP) because they are believed to represent model systems that may be predictive of clinical efficacy of pharmacotherapies for cocaine dependence. The data generated by this contract will be utilized by the NIDA/MDD/CTDP in the selection of compounds for additional preclinical evaluation and subsequent development as pharmacotherapies for cocaine dependence. Briefly, the Contractor will be screening compounds in the mouse locomotor activity and rat drug discrimination test. We respect to the locomotor activity procedure, the effect of the compound, administered alone and in combination with cocaine, on locomotor activity in mice will be assessed. Depending on results obtained from the locomotor activity test, the compound will either be evaluated for the ability to antagonize the discriminative (subjective) effects of cocaine or to substitute for the discriminative (subjective) effects of cocaine. The anticipated end results of this contract will be written reports detailing study findings.